When is Pfizer's Earnings Call?

Pfizer's (NYSE: PFE) next earnings call is anticipated to be around November 4, 2025, for the third quarter of 2025. This call is a crucial event for investors, analysts, and the public to gain insights into the pharmaceutical giant's financial performance, strategic direction, and future outlook. Understanding the details of this call, including how to access it and what topics will be discussed, is essential for anyone tracking the company's progress.

Key Information

Pfizer's (NYSE: PFE) next earnings call is expected to take place on or around November 4, 2025, to discuss the company's third-quarter 2025 financial results. While the exact time for the November call is not yet confirmed, Pfizer's earnings calls typically commence at 10:00 AM EDT (Eastern Daylight Time). Some sources also indicate October 28, 2025, as a potential announcement date for the earnings release.

Investors and interested parties can typically access the earnings call through several channels:

• Webcast: A live webcast is usually available on the Pfizer Investor Relations website at pfizer.com/investors. It is often advisable to register in advance for the webcast.
• Conference Call (Phone): Participants can generally listen to the conference call by dialing 800-456-4352 (U.S. and Canada) or 785-424-1086 (Outside U.S. and Canada). A passcode is typically required; for instance, the Q2 2025 call used "49385".
• Replay: A transcript and webcast replay of the call are usually made available on the Pfizer Investor Relations website within 24 hours after the live call and remain accessible for at least 90 days.

During the call, Pfizer's management, including Chairman and CEO Dr. Albert Bourla and CFO David Denton, will deliver prepared remarks followed by a question and answer (Q&A) session with investment analysts. Key topics expected to be discussed include:

• Detailed financial results for Q3 2025, covering revenue, earnings per share (EPS), and comparisons to previous periods and analyst forecasts.
• Updates to full-year revenue and EPS guidance, along with projections for future periods.
• Discussions on operational performance, including factors driving revenue growth from new and acquired products, and operational efficiencies.
• Progress updates on the research and development (R&D) pipeline, including clinical trial results and potential new drug indications.
• Information on the company's strategic initiatives, such as cost improvement programs, margin expansion, and the integration of technologies like AI and automation.
• Insights into market dynamics, competitive pressures, patent expirations, geopolitical factors, and the impact of policy discussions (e.g., IRA Medicare Part D redesign).
• Potential future business development activities, including mergers, acquisitions, or licensing agreements.

Analysts are currently estimating an EPS of $0.75 for Pfizer's Q3 2025.

Context and Background

Earnings calls are a standard practice for publicly traded companies like Pfizer (NYSE: PFE) to transparently communicate their financial health and strategic direction to the market. These calls typically occur quarterly, following the release of the company's financial statements. For a pharmaceutical company like Pfizer, these calls are particularly significant due to the long development cycles of drugs, the impact of patent expirations, and the continuous need for innovation and pipeline replenishment.

Historically, Pfizer's earnings calls have provided critical updates on its diverse portfolio, which spans vaccines, oncology, internal medicine, and rare diseases. The company has navigated significant shifts, including the immense success of its COVID-19 vaccine and antiviral treatments, followed by a period of normalization and strategic adjustments. Compared to other large pharmaceutical companies, Pfizer often faces unique challenges and opportunities related to its scale, global presence, and extensive R&D pipeline. Relevant trends impacting Pfizer include the increasing focus on precision medicine, the rise of biosimilars, evolving regulatory landscapes, and the growing importance of digital health and AI in drug discovery and development.

Implications

The upcoming Q3 2025 earnings call for Pfizer (NYSE: PFE) carries several implications for the company, its investors, and the broader pharmaceutical industry.

• Short-term implications: The immediate impact will likely be seen in Pfizer's stock price. Positive financial results, strong guidance, or promising pipeline updates could lead to an upward movement, while disappointing figures or cautious outlooks might result in a decline. Investors will be particularly keen on the Q3 performance relative to analyst estimates and any adjustments to the full-year 2025 guidance. Updates on key product sales and the performance of recent acquisitions will also be closely watched.
• Long-term outlook: The call will offer insights into Pfizer's long-term strategy, particularly regarding its post-COVID-19 growth drivers. Discussions around the R&D pipeline, potential new drug approvals, and strategic investments in areas like oncology and rare diseases will shape the perception of Pfizer's sustainable growth trajectory. The company's ability to effectively manage patent expirations and integrate new assets will be crucial for its long-term revenue stability and growth.
• Factors that could change the situation: Several factors could influence the outcomes discussed during the call and Pfizer's future performance. These include unexpected clinical trial results (positive or negative), regulatory approvals or rejections, competitive landscape shifts (e.g., new market entrants or competitor drug launches), changes in healthcare policy (such as drug pricing reforms), and broader macroeconomic conditions affecting healthcare spending and access. Geopolitical events and supply chain disruptions could also impact operations and financial results.

Summary

Pfizer's (NYSE: PFE) next earnings call is anticipated around November 4, 2025, providing a critical update on its third-quarter 2025 financial performance and strategic direction. This event, typically accessible via webcast and conference call, will feature discussions on financial results, future guidance, R&D pipeline progress, and strategic initiatives. It serves as a vital opportunity for stakeholders to assess Pfizer's current health and future prospects, with implications for its stock performance and long-term position in the global pharmaceutical market. Investors will be particularly focused on the company's ability to deliver on its financial targets and advance its diverse portfolio in a dynamic healthcare environment.